Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.
Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.